Opioid Post-Market Study Faces Recruitment, Efficacy Challenges
Executive Summary
Industry’s proposed design for a clinical trial on opioid-induced hyperalgesia may be overly ambitious, stakeholders say at an FDA meeting, citing potential hurdles to enrolling and retaining patients.